ZA200303723B - Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders. - Google Patents
Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders. Download PDFInfo
- Publication number
- ZA200303723B ZA200303723B ZA200303723A ZA200303723A ZA200303723B ZA 200303723 B ZA200303723 B ZA 200303723B ZA 200303723 A ZA200303723 A ZA 200303723A ZA 200303723 A ZA200303723 A ZA 200303723A ZA 200303723 B ZA200303723 B ZA 200303723B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- pain
- formula
- phenyl
- cancer
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims description 15
- 230000036506 anxiety Effects 0.000 title claims description 15
- 208000019906 panic disease Diseases 0.000 title claims description 6
- 229940122203 Bombesin receptor antagonist Drugs 0.000 title description 17
- 108090000765 processed proteins & peptides Proteins 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims description 115
- 238000000034 method Methods 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 35
- 238000012360 testing method Methods 0.000 claims description 30
- -1 nitro, amino Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 238000002059 diagnostic imaging Methods 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 108010073466 Bombesin Receptors Proteins 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 230000036407 pain Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 239000002254 cytotoxic agent Substances 0.000 claims description 9
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 9
- 230000002496 gastric effect Effects 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 229940080818 propionamide Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 201000010275 acute porphyria Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 230000007040 lung development Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000008439 repair process Effects 0.000 claims description 7
- 230000003248 secreting effect Effects 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 208000033552 hepatic porphyria Diseases 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 208000009935 visceral pain Diseases 0.000 claims description 6
- 206010012559 Developmental delay Diseases 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- 206010041250 Social phobia Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 206010019375 Helicobacter infections Diseases 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 208000000718 duodenal ulcer Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 208000010642 Porphyrias Diseases 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 15
- 108010051479 Bombesin Proteins 0.000 description 13
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 13
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 13
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 13
- 229940125904 compound 1 Drugs 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 239000002790 bombesin antagonist Substances 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 9
- 206010047700 Vomiting Diseases 0.000 description 9
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000000949 anxiolytic effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 229960003529 diazepam Drugs 0.000 description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 208000022531 anorexia Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 230000036544 posture Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000003997 social interaction Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
- 102100038819 Neuromedin-B Human genes 0.000 description 4
- 101800001639 Neuromedin-B Proteins 0.000 description 4
- 206010053552 allodynia Diseases 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229960002464 fluoxetine Drugs 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 241001515942 marmosets Species 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- YPFNACALNKVZNK-MFNIMNRCSA-N (2s)-2-[(2-aminoacetyl)amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3r)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1- Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CN)[C@@H](C)O)C1=CC=CC=C1 YPFNACALNKVZNK-MFNIMNRCSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 241000282339 Mustela Species 0.000 description 3
- 229920005439 Perspex® Polymers 0.000 description 3
- 208000034972 Sudden Infant Death Diseases 0.000 description 3
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RWBLWXCGQLZKLK-USVTTYPOSA-N (2s)-2-[(2-aminoacetyl)amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxob Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CN)C(C)C)C1=CN=CN1 RWBLWXCGQLZKLK-USVTTYPOSA-N 0.000 description 2
- NNFUWNLENRUDHR-HKBQPEDESA-N (2s)-3-(1h-indol-3-yl)-n-[[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl]-2-methyl-2-[(4-nitrophenyl)carbamoylamino]propanamide Chemical compound N1=CC(OC)=CC=C1C1(CNC(=O)[C@](C)(CC=2C3=CC=CC=C3NC=2)NC(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCCCC1 NNFUWNLENRUDHR-HKBQPEDESA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000288950 Callithrix jacchus Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 101800001638 Neuromedin-C Proteins 0.000 description 2
- 206010038776 Retching Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000002895 emetic Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000012346 open field test Methods 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- YEESWKBQGRKYCN-VETVTEPKSA-N (2r)-2-[(2,2-dimethyl-1-phenylpropyl)carbamoylamino]-n-[2,6-di(propan-2-yl)phenyl]-3-(1h-indol-3-yl)propanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)[C@H](NC(=O)NC(C=1C=CC=CC=1)C(C)(C)C)CC1=CNC2=CC=CC=C12 YEESWKBQGRKYCN-VETVTEPKSA-N 0.000 description 1
- AFDXUTWMFMAQJO-PMERELPUSA-N (2s)-3-(1h-indol-3-yl)-2-methyl-2-[(4-nitrophenyl)carbamoylamino]-n-[(1-pyridin-2-ylcyclohexyl)methyl]propanamide Chemical compound N([C@](CC=1C2=CC=CC=C2NC=1)(C)C(=O)NCC1(CCCCC1)C=1N=CC=CC=1)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 AFDXUTWMFMAQJO-PMERELPUSA-N 0.000 description 1
- ILJBXVQOPJTFJY-PMERELPUSA-N (2s)-3-(1h-indol-3-yl)-2-methyl-n-[(1-pyridin-2-ylcyclohexyl)methyl]-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]propanamide Chemical compound N([C@](CC=1C2=CC=CC=C2NC=1)(C)C(=O)NCC1(CCCCC1)C=1N=CC=CC=1)C(=O)NC1=CC=C(C(F)(F)F)C=C1 ILJBXVQOPJTFJY-PMERELPUSA-N 0.000 description 1
- FKOHSYGDMKTNKS-YTTGMZPUSA-N (2s)-n-(cyclohexylmethyl)-2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-3-(1h-indol-3-yl)-2-methylpropanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)N[C@](C)(C(=O)NCC1CCCCC1)CC1=CNC2=CC=CC=C12 FKOHSYGDMKTNKS-YTTGMZPUSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- JJUSUGQWCMVNSF-UHFFFAOYSA-N 2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-2-methyl-3-(2-nitrophenyl)-n-[(1-pyridin-2-ylcyclohexyl)methyl]propanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C)(C(=O)NCC1(CCCCC1)C=1N=CC=CC=1)CC1=CC=CC=C1[N+]([O-])=O JJUSUGQWCMVNSF-UHFFFAOYSA-N 0.000 description 1
- HYQCNAAFWMAPKP-UHFFFAOYSA-N 2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-2-methyl-3-pyridin-2-yl-n-[(1-pyridin-2-ylcyclohexyl)methyl]propanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C)(C(=O)NCC1(CCCCC1)C=1N=CC=CC=1)CC1=CC=CC=N1 HYQCNAAFWMAPKP-UHFFFAOYSA-N 0.000 description 1
- PANLPYYFPCVXCU-UHFFFAOYSA-N 2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-2-methyl-n-[(1-pyridin-2-ylcyclohexyl)methyl]-3-[2-(trifluoromethyl)phenyl]propanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C)(C(=O)NCC1(CCCCC1)C=1N=CC=CC=1)CC1=CC=CC=C1C(F)(F)F PANLPYYFPCVXCU-UHFFFAOYSA-N 0.000 description 1
- BIXFCYGRNASFJZ-UHFFFAOYSA-N 2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-3-(1h-imidazol-5-yl)-n-[(1-pyridin-2-ylcyclohexyl)methyl]propanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C(=O)NCC1(CCCCC1)C=1N=CC=CC=1)CC1=CNC=N1 BIXFCYGRNASFJZ-UHFFFAOYSA-N 0.000 description 1
- BCUIXRZIPCRVGV-UHFFFAOYSA-N 2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-3-(1h-indol-3-yl)-2-methyl-n-(1,2,3,4-tetrahydronaphthalen-1-yl)propanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C)(C(=O)NC1C2=CC=CC=C2CCC1)CC1=CNC2=CC=CC=C12 BCUIXRZIPCRVGV-UHFFFAOYSA-N 0.000 description 1
- YINQWZPBGNQVOW-UHFFFAOYSA-N 2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-3-(1h-indol-3-yl)-2-methyl-n-phenylpropanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C)(C(=O)NC=1C=CC=CC=1)CC1=CNC2=CC=CC=C12 YINQWZPBGNQVOW-UHFFFAOYSA-N 0.000 description 1
- CNXIVIXTRWDXOA-UHFFFAOYSA-N 2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-3-(1h-indol-3-yl)-2-methylpropanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C)(C(N)=O)CC1=CNC2=CC=CC=C12 CNXIVIXTRWDXOA-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- SQISOBNEDVJTMH-UHFFFAOYSA-N 3-(1h-indol-3-yl)-2-methyl-2-[1-(4-nitrophenyl)ethylcarbamoylamino]-n-[(1-pyridin-2-ylcyclohexyl)methyl]propanamide Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(C)NC(=O)NC(C)(CC=1C2=CC=CC=C2NC=1)C(=O)NCC1(C=2N=CC=CC=2)CCCCC1 SQISOBNEDVJTMH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- BFVFOJHFCINJSJ-UHFFFAOYSA-N 4-[[1,7-dioxo-4-[3-oxo-3-(phenylmethoxyamino)propyl]-1,7-bis(phenylmethoxyamino)heptan-4-yl]amino]-4-oxobutanoic acid Chemical compound C=1C=CC=CC=1CONC(=O)CCC(CCC(=O)NOCC=1C=CC=CC=1)(NC(=O)CCC(=O)O)CCC(=O)NOCC1=CC=CC=C1 BFVFOJHFCINJSJ-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940123804 Bombesin antagonist Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001326189 Gyrodactylus prostae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 241000269800 Percidae Species 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 206010036940 Prostatic adenoma Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000009985 maternal smoking Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- QWWWLHMZEMLRPB-UHFFFAOYSA-N n-(cyclohexylmethyl)-2-[(2,6-dichlorophenyl)carbamoylamino]-3-(1h-indol-3-yl)-2-methylpropanamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C(=O)NCC1CCCCC1)NC(=O)NC1=C(Cl)C=CC=C1Cl QWWWLHMZEMLRPB-UHFFFAOYSA-N 0.000 description 1
- BUKVFXISAYYMOI-UHFFFAOYSA-N n-(cyclohexylmethyl)-2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-2-methyl-3-pyridin-2-ylpropanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C)(C(=O)NCC1CCCCC1)CC1=CC=CC=N1 BUKVFXISAYYMOI-UHFFFAOYSA-N 0.000 description 1
- ZRFXLZPTZXNZSP-UHFFFAOYSA-N n-[(1-hydroxycyclohexyl)methyl]-3-(1h-indol-3-yl)-2-methyl-2-[(4-nitrophenyl)carbamoylamino]propanamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C(=O)NCC1(O)CCCCC1)NC(=O)NC1=CC=C([N+]([O-])=O)C=C1 ZRFXLZPTZXNZSP-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SCTCPNNBVHLGJR-UHFFFAOYSA-N n-cyclohexyl-2-[[2,6-di(propan-2-yl)phenyl]carbamoylamino]-3-(1h-indol-3-yl)-2-methylpropanamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NC(C)(C(=O)NC1CCCCC1)CC1=CNC2=CC=CC=C12 SCTCPNNBVHLGJR-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- QJQAMHYHNCADNR-UHFFFAOYSA-N n-methylpropanamide Chemical compound CCC(=O)NC QJQAMHYHNCADNR-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001956 orexigenic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004351 phenylcyclohexyl group Chemical group C1(=CC=CC=C1)C1(CCCCC1)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
NOVEL USES OF NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS FOR TREATING ANXIETY . AND PANIC DISORDERS
This invention relates to the use of bombesin receptor antagonists for the Co - “manufacture of medicaments for novel indications. Tt also relates to methods for diagnosis, treatment or prevention using the bombesin receptor antagonists.
The amphibian tetradecapeptide bombesin (BB) belongs to a novel class of peptides that share structural homology within their C-terminal sequences (Dutta
A.S. (1993) in Small Peptides: Chemistry, Biology, & Clinical Studies, Chapter 2, pp 66-82, Elsevier).
The decapeptides neuromedin B (NMB) and neuromedin C (NMC) and a 27 residue amino acid, gastrin-releasing peptide (GRP), are the three mammalian bombesin-like peptides to have thus far been identified (Battey J. et al. (1991),
Trends Neurosci. 14: 524). NMB and GRP are believed to mediate a variety of peripheral and centrally mediated biological actions by acting upon the corresponding NMB-preferring (BB) and GRP-preferring (BB») receptors (Lebacg-
Verheyden A. et al. (1990) Handbook of Experimental Pharmacology 95 (Part II): 71). International patent application WO 98/07718 describes non-peptide bombesin receptor antagonists. . SUMMARY OF THE INVENTION ’ It has now been discovered that compounds described in WO 98/07718 and related compounds may be useful for the diagnosis, prevention, or treatment of anxiety and panic disorders, pulmonary hypertension, lung repair and lung development disorders, prostate cancer, pancreatic cancer, hepatic porphyria, visceral pain, gastrointestinal secretory disturbances, emesis or anorexia. The bombesin . receptor antagonists utilised in the instant invention are described in the international patent application WO 98/07718 whose disclosure is incorporated herein by ' reference. oo oo - “This ifivention therefore provides a method for preventing or treating various diseases amenable to therapy by a bombesin receptor antagonist, including anxiety and panic disorders, social phobia, pulmonary hypertension, lung repair and lung development disorders, prostate cancer, pancreatic cancer, hepatic porphyria, visceral pain, gastrointestinal secretory disturbances, emesis or anorexia, inflammatory pain, neuropathic pain, cancer pain, postoperative pain, trigeminal neuralgia pain, acute herpetic and post herpetic pain, said method comprising administering to a patient in need of such treatment an effective amount of a bombesin receptor antagonist of Formula I 3 Pel fF
Rar aa fry de * : Ar ’ ® or a pharmaceutically acceptable salt thereof wherein jisOor 1; kisOorl; 11s 0,1, 2, or 3; misOor 1; nis0,1 or2;
Ar is phenyl, pyridyl or pyrimidyl, each unsubstituted or substituted by from 1 to 3 substituents selected from alkyl, halogen, alkoxy, acetyl, nitro, amino, - ) CH)NR10R 11, cyano, -CF3, -NHCONHp, and -COR12;
R1lis hydrogen or straight, branched, or cyclic alkyl of from 1 to 7 carbon } atoms;
R8 is hydrogen or forms a ring with R! of from 3 to 7 carbon atoms;
RZ is hydrogen or straight, branched, or cyclic alkyl of from 1 to 8 carbon . atoms which can also contain 1 to 2 oxygen or nitrogen atoms;
RY is hydrogen or forms a ring of from 3 to 7 carbon atoms with R2 which ! can contain an oxygen or nitrogen atom; or R2 and RY can together be a carbonyl, . So -- Ar! can be independently selected from Ar and can also include pyridyl-N- oxide, indolyl, imidazolyl, and pyridyl;
R4, R3, RS, and R7 are each independently selected from hydrogen and lower alkyl; R4 can also form with R5 a covalent link of 2 to 3 atoms which may include an oxygen or a nitrogen atom;
R3 can be independently selected from Ar or is hydrogen, hydroxy, -NMep,
N-methyl-pyrrolyl, imidazolyl, N-methyl-imidazolyl, tetrazolyl, N-methyl- tetrazolyl, thiazolyl, -CONRI3RM, alkoxy, <7] / 8 ‘ A i) [¢) 0 a. oC °F
Ar? 0} , Of Ar? CF, whereinpisO,1or2 and Ar2 is phenyl or pyridyl;
R10 R11 RI2Z R13 and R14 are each independently selected from hydrogen or straight, branched, or cyclic alkyl of from 1 to 7 carbon atoms.
This invention also concerns the use of a compound of Formula I for the ) 20 preparation of a medicament useful for diagnosing, preventing or treating diseases amenable to therapy by a bombesin receptor antagonist as described above.
The present invention also provides a method for treating a mammalian tumour which comprises administering to a mammal a composition comprising a tumour-inhibiting amount of a compound of Formula I, or of a conjugate of a cytotoxic agent with a compound of Formula I. ‘ The present invention further provides a method for in vivo diagnostic imaging of a mammalian tissue which has cell surface bombesin receptors, which includes Co -- administering to a mammal a diagnostic imaging amount of a radiolabelled compound of the present invention, and further detecting a radiation image due to the binding of said compound to the bombesin receptors of a tissue having an abundance of cells with such receptors. In particular, this invention relates to a method for diagnosing a mammal for the presence of a mammalian tumour which comprises administering to a mammal a diagnostic imaging amount of a compound of Formula I, and optionally detecting an image of a tissue having an abundance of cells with bombesin receptors.
A further aspect of the present invention provides a method for in vitro detection of a cancer cell in a mammalian tissue, which includes contacting a mammalian tissue sample with an in vitro diagnostic imaging amount of a compound of Formula I for a time and under conditions sufficient for binding of the compound to the cancer cell, and detecting such binding.
Figure 1 shows the effects of Compound 1 (at 10 mg/kg, i.p. 1 h before test) on the behaviour of rats placed on the elevated plus-maze ([ A]: % time on open arms;
B1: % number of open arm entries; [ C]: Open end time; Veh.: vehicle).
Figure 2 shows the effects of Compound 1 on time spent in social interaction . by rats in high light, unfamiliar conditions.
Figure 3 shows the effects of Compound 1 on the time spent by rats in the ) central region of the arena in the open field test (Veh.: vehicle).
Figure 4 shows the effects of Compound 1 in the isolation-induced vocalisation model of anxiety in the guinea pig pup.
Figure 5 shows the effect of diazepam (a) or fluoxetine (b) in the isolation- . induced vocalisation model of anxiety in the guinea pig pup. : DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
Ce _ The compounds used in the invention are those of Formula I above.
Preferred compounds are those of Formula II w YP (0
Ar J - NTETeTN TS R3 {C o] Al an wherein
Ar is phenyl unsubstituted or substituted with 1 or 2 substituents selected from isopropyl, halo, nitro, and cyano;
R4, RS, and RS are hydrogen;
R7 is methyl or hydrogen;
R3 is 2-pyridyl or hydroxy; and
Ar! is indolyl, pyridyl, pyridyl-N-oxide, or imidazolyl.
Other preferred compounds are those of Formula I wherein
Ar is unsubstituted phenyl;
Rlis cyclopentyl or tert butyl;
R#4 and RS are hydrogen;
R7 is methyl;
RO is hydrogen;
R3 is phenyl with two isopropyl substituents, unsubstituted phenyl, or
, 0 0 \ ; and _ } Arl is indolyl. Co ) oo
Other preferred compounds are those of Formula I wherein Ar is 2,6- diisopropyl-phenyl, 4-nitro-phenyl, and 4-cyano-phenyl;
R4, RS, and RO are hydrogen;
R7 is methyl;
R2 is hydrogen or cyclohexyl; and :
R3 is hydroxyl, pyridyl, 0]
Sel oa a > , Or .
The alkyl groups of the compounds used in the invention include straight, branched, or cyclic carbon chains of from 1 to 8 carbon atoms except where specifically stated otherwise. Representative groups are methyl, ethyl, propyl, isopropyl, n-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, 2-methylhexyl, n-pentyl, I- methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl, and the like. . 20 The lower alkyl groups of the compounds used in the invention comprise those having 1 to 6 carbon atoms.
The cycloalkyl groups of the compounds used in the invention comprise those having 3 to 7 carbon atoms. They may be substituted with from 1 to 3 groups selected from halogens, nitro, alkyl, and alkoxy.
The alkoxy groups of the compounds used in the invention comprise both straight and branched carbon chains of from 1 to 6 carbon atoms unless otherwise - stated. Representative groups are methoxy, ethoxy, propoxy, i-propoxy, t-butoxy, and hexoxy.
The term "halogen" is intended to include fluorine, chlorine, bromine, iodine and astatine, including radionuclides thereof.
The term "Ar" is intended to include substituted or unsubstituted phenyl. The substituents include one or more substituents such as halogens, nitro, alkyl, alkoxy, and others as specified or as would occur to one skilled in the art.
The term "amine" is free amino, alkylated amines, and acylated amines.
More preferred compounds are selected from (S) N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)- 2-methyl-propionamide;
N-Cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1 H-indol-3-yI)-
N-methyl-propionamide;
N-Cyclohexylmethyl-2-[3-(2,6~diisopropyl-phenyl)-1-methyl-ureido]-3-(1H- indol-3-yl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-(1-oxy-pyridin-2-yl)-N-(1- pyridin-2-yl-cyclohexylmethyl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-pyridin-2-yl-N-(1-pyridin-2- yl-cyclohexylmethyl)-propionamide; 2-[3-(2-tert-Butyl-phenyl)-ureido]-N-cyclohexylmethyl-3-(1H-indol-3-yl)-2- . methyl-propionamide;
N-Cyclohexylmethyl-2-[3-(2,6-dichloro-phenyl)ureido]-3-(1H-indol-3-yl)-2- methyl-propionamide;
N-Cyclohexylmethyl-2-[3-(2,6-dimethoxy-phenyl)ureido]-3-(1H-indol-3-y1)-2- methyl-propionamide;
N-Cyclohexylmethyl-2-[3-(2,6-dimethylamino-phenyl)-ureido}-3-(1Hindol-3- : yl)-2-methyl-propionamide; (S) N-Cyclohexylmethyl-3-(1H-indol-3-yl)-2-methyl-2-[ 3-(4-nitro-phenyl)- oo - ureido]-propionamide;
N-Cyclohexylmethyl-2-[3-(2,2-dimethyl- 1 -phenyl)propyl)-ureido]-3-(1 Hindol- 3-yl)-2-methyl-propionamide; [S-(R*, R*)] 3-(1H-Indol-3-yl)-2-methyl-2-{3-[1-(4-nitro-phenyl)-ethyl]- ureido}-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide;
N-(2,2-Dimethyl-4-phenyl-[1,3]dioxan-5-yl)-3-(1H-indol-3-yl)-2-methyl-2-[ 3- (1-phenyl-cyclopentylmethyl)ureido}-propionamide; (8)-N-(2,6-Diisopropyl-phenyl)-2-[3-(2,2-dimethyl-1-phenyl-propyl)-ureido]- 3-(1H-indol-3-yl)-propionamide; (R)-N-(2,6-Diisopropyl-phenyl)-2-[3-(2,2-dimethyl-1-phenyl-propyl)-ureido]- 3-(1H-indol-3-yl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-(2,2-dimethyl-4-phenyl-[ 1,3 ]dioxan- 5-y1)-3-(1H-indol-3-yl)-2-methyl-propionamide;
N-Cyclohexyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2- methyl-propionamide;
N-(2-Cyclohexyl-ethyl)-2-{3-(2,6-diisopropyl-phenyl)-ureido}-3-(1H-indol-3- y1)-2-methyl-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl- propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3~(1H-indol-3-yl)-2-methyl-N(3- methyl-butyl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N(3- - phenyl-propyl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(1,2,3,4- tetrahydro-naphthalen-1-yl)-propionamide;
2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(2- . phenyl-cyclohexyl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-indan-1-yl-3-(1H-indol-3-yl)-2- ‘ methyl-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-N-(I-hydroxy-cyclohexylmethyl)3-(1H- oo _ indol-3-yl)-2-methyl-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-y1)-2-methyl-N-(1- pyridin-2-yl-cyclohexylmethyl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N(6,7,8,9- tetrahydro-5H-benzocyclohepten-5-yl)-propionamide; 2-[3-(2,6-diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-phenyl- propionamide;
N-(1 -Hydroxy-cyclohexylmethyl)-3-(1H-indol-3-yl)-2-methyl-2-[3-(4-nitro- phenyl)-ureido]-propionamide; 2-[3-(4-cyano-phenyl)-ureido] 3-(1H-indol-3-yl)-2-methyl-N-(1-pyridin-2-yl- cyclohexylmethyl)-propionamide; (S) 3-(1H-indol-3-yl)-2-methyl-2-[3-(4-nitro-phenyl)-ureido}-N-(1-pyridin-2- yl-cyclohexylmethyl)-propionamide; (S) 3-(1H-indol-3-yl)-2-methyl- N-(1-pyridin-2-yl-cyclohexylmethyl)-2-[3-(4- trifluoromethyl-phenyl)-ureido]-propionamide; (S) 4-(3- {2-(1H-indol-3-yl)-1-methyl-1-{ (1-pyridin-2-yl-cyclohexylmethyl)- carbamoyl]-ethyl}-ureido)-benzoic acid ethyl ester; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-imidazol-4-yl)-N-(1-pyridin-2- yl-cyclohexylmethyl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-N-(1-pyridin-2-yl- cyclohexylmethyl)-3-(2-trifluoromethyl-phenyl)-propionamide; 2-[3-(2,6-Diisopropyl-phenyl)-ureido]-2-methyl-3-(2-nitro-phenyl)-N-(1- - pyridin-2-yl-cyclohexylmethyl)-propionamide; (S) 3-(1H-Indol-3-yl)-N-[1-(5-methoxy-pyridin-2-yl)-cyclohexylmethyl]-2- methyl-2-[3-(4-nitro-phenyl)-ureido]-propionamide; and
N-cyclohexylmethyl-2-[3-(2,6-diisopropyl-phenyl)-ureido]-2-methyl-3- pyridin-2-yl-propionamide.
Hereinafter, (S) 3-(1H-Indol-3-yl)-N-[1-(5-methoxy-pyridin-2-yl)- cyclohexylmethyl]-2-methyl-2-[3-(4-nitro-phenyl)-ureido]-propionamide is also i — referred to as Compound 1.
The compounds used in the present invention can have multiple chiral centers in the above Formula I depending on their structure. In particular, the compounds used in the present invention may exist as diastereomers, mixtures of diastereomers, or as the mixed or the individual optical enantiomers. The present invention contemplates use of all such forms of the compounds.
The compounds utilized in the invention include solvates, hydrates, pharmaceutically acceptable salts, and polymorphs (different crystalline lattice descriptors) of the compounds of Formula I.
Where it is appropriate to form a salt, the pharmaceutically acceptable salts include acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium acetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoloylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, theoclate, triethiodide, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, . procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. (See also "Pharmaceutical salts” by Berge S.M. et al. (1997) J. Pharm. Sci. 66: 1-19, which is incorporated herein by reference.)
The terms "patient" or "subject" are intended to include a mammal, especially ) a human. : The methods of this invention are carried out by administering to a mammal an effective amount of a compound of Formula I, in chemotherapeutic indications a oo —- conjugate of a compound of Formula I with a cytotoxic agent, or a pharmaceutically acceptable salt thereof, to diagnose, prevent or treat any of the disorders hereinbefore described. Such effective amount will generally be from about 1 to about 300 mg per kg of subject body weight. Typical doses will be from about 1 mg to about 5 g per day for an adult of 70 kg. In addition, doses of radiolabelled compounds used depend on the specific radioactivity of the radionuclide.
In a further aspect of the present invention, there is provided a pharmaceutical composition for the treatment or prevention of the indications hereinbefore recited, said composition comprising a bombesin receptor antagonist of Formula I, together with at least one pharmaceutically acceptable carrier or excipient. For preparing pharmaceutical compositions from the compounds used in this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, pessaries and suppositories including vaginal suppositories. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid that is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. - For preparing pessary or suppository preparations, a Jow-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
Ointments are also preferred pharmaceutical compositions that can be similarly prepared from the compounds used in this invention.
The powders and tablets preferably contain 5% to about 70% of the active component. Suitable carriers are magnesium carbonate, magnesium stearate, talc, LL — lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
The term "preparation" is intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.
Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
Liquid form preparations include solutions, suspensions, and emulsions.
Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium } carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
Preferably the pharmaceutical preparation 1s in unit dosage form. In such form, the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, } capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these ) packaged forms. ] As already mentioned, the compounds of Formula I can be used for the diagnosis, prevention and treatment of various disease states. Further information on such uses is provided below. 1) ANXIETY, PANIC ATTACKS AND SOCIAL PHOBIA
Anxiety is a very commonly observed symptom, for which benzodiazepines are the primary treatment agents. Chlordiazepoxide, diazepam, oxazepam, lorazepam, prazepam and alprazolam are most commonly used for this purpose in the United
States. However anxiolytic benzodiazepines may also cause sedation, they have muscle-relaxant, sedative-hypnotic, and ammestic side effects; they also tend to potentiate the effects of alcohol. Some tolerance to their effects may develop, withdrawal after chronic use frequently induces rebound anxiety, and long-term use of benzodiazepines, particularly with escalating doses, can lead to dependence.
Therefore there is a need for anxiolytic treatments with a reduced dependence liability.
Recent findings may suggest a role of bombesin-like peptides in stress and anxiety (Plamondon H. ef al. (1996) Soc. Neurosci. 22: Abstract 181.13): antisense oligonucleotides to mRNA for GRP receptors and NMB receptors were infused i.c.v. in rats over 2 days, resulting in a reduction of bombesin binding site density in the brain, as measured by receptor autoradiography. Rats treated with the antisense : oligonucleotides spent significantly more time on the anxiogenic fields of an elevated plus maze, or of a trough-tunnel oval maze, reflecting an anxiolytic effect of treatment, as compared to control animals. The compounds of the instant invention are useful in the treatment of anxiety and of panic as demonstrated by means of pharmacological procedures, some of which are exemplified below.
Animals and Drug administration 8) — - Male Hooded Lister rats (200-250 g) or male TO mice (20-25 g) are housed in groups of six. Common marmosets (Callithrix jacchus) weighing 280-380 g are housed in pairs. All animals are housed under a 12-hour light/dark cycle, with food and water ad libitum. - Unless otherwise specified, drugs are administered intraperitoneally (i.p.) or subcutaneously (s.c.) 40 min before the test in a volume of 1 ml/kg for rats and marmosets and 10 ml/kg for mice. a) Mouse light/dark box test
The apparatus is an open-topped box, 45 cm long, 27 cm wide, and 27 cm high, divided into a small (2/5) and a large (3/5) area by a partition that extends 20 cm above the walls (Costall B. ef al. (1989) Pharmacol. Biochem. Behav. 32: 777-785).
Thereis a 7.5 x 7.5 cm opening in the center of the partition at floor level. The small compartment is painted black and the large compartment white. The white compartment is illuminated by a 60-W tungsten bulb. The laboratory is illuminated by red light. Each mouse is tested by placing it in the center of the white area and allowing it to explore the novel environment for 5 min; the time spent in the illuminated site is measured (Kilfoil T. ez al. (1989) Neuropharmacol. 28: 901-905). b) Rat elevated X-maze test
Methods: A standard elevated X-maze (Handley S.L. et al.(1984) Naunyn-
Schiedeberg's Arch. Pharmacol. 327: 1-5) was automated as described by Field et al. (1991) Br. J. Pharmacol. 102 Suppl.: 304P. The animals are placed on the center of the X-maze facing one of the open arms. For determining anxiolytic effects, the entries and time spent on the end half sections of the open arms is measured during the 5-minute test period (Costall et al. (1989) Br. J. Pharmacol. 96 Suppl.: 312P).
Results: (Figure 1) In rats given Compound 1 at the dose of 10 mg/kg i.p. 60 min or before the test, there was a significant increase in % time spent on the open arms of the maze, and also in the amount of time spent exploring the ends of the open arms, as compared with rats receiving only the vehicle. c) Marmoset human threat test
The total number of body postures exhibited by the animals towards the threat stimulus (a human standing approximately 0.5 m away from the marmoset cage and staring into the eyes of the marmoset) is recorded during the 2-minute test period. The body postures scored are slit stares, tail postures, scent marking of the cage/perches, piloerection, retreats, and arching of the back. Each animal is exposed to the threat stimulus twice on the test day before and after drug treatment. Drug treatment is carried out s.c. at least 2 h after the first (control) threat; the pretreatment time for each compound is 40 min. The difference between the two scores is analyzed using one-way analysis of variance followed by Dunnett's t-test. d) Rat conflict test
Rats are trained to press levers for food reward in operant chambers. The schedule consists of alternations of four 4-minute unpunished periods on variable interval of 30 s signalled by chamber lights on, and three 3-minute punished periods on fixed ratio 5 (by footshock concomitant to food delivery) signalled by chamber : lights off. The degree of footshock is adjusted for each rat to obtain approximately 80 % to 90 % suppression of responding in comparison with unpunished responding.
Rats receive saline vehicle on training days.
f) Rat social interaction test
Methods: The social interaction arena is circular (diameter 70 cm) and made of white perspex with walls 30 cm high. The arena is lit by a bright light source (350 lux) located directly above the arena. A camera, linked to a video recorder in an adjacent - room, is also located directly above the arena to allow the test sessions to be recorded oo for later analysis.
Rats are allocated to a partner on the basis of body weight, so that members of a pair do not differ by more than 10 g. Both rats in each pair are injected i.p. with either vehicle (n = 10) or various doses of the test compound (n= 10/group) 60 min prior to being placed into the arena for a period of 5 min. Time spent in active social investigation (sniffing, following and grooming the partner) is recorded by an observer blind to drug treatment. Testing is performed between 10:00 and 14:00 h in an order randomized for drug treatment, and the arena thoroughly wiped after each trial. Data are analyzed by one-way ANOVA, followed by post-hoc Duncan’s tests for individual differences.
Results: (Figure 2) Compound 1 significantly increased levels of social interaction of the rats at both 3.75 and 7.5 mg/kg [F(2,27) = 7.2 , p<0.01]. In terms of percent increase, the two doses were similar. There was no effect on locomotor activity, thereby indicating the effect to be selective to levels of social interaction. g) Rat open field test
Methods: The open field arena is circular (diameter 70 cm) and made of white perspex with walls 30 cm high. The arena is lit by a bright light source (350 lux) : located directly above the arena. A camera, linked to a video recorder in an adjacent room, is also located directly above the arena to allow the test sessions to be recorded for later analysis. The floor is divided into an inner and outer circle by a line. Sixty minutes after dosing, each rat is placed in the center of the arena for 5 min and left to explore. An observer blind to drug treatment scores the time spent near the perimeter of the arena, and the time spent in the inner area of the arena. The animal is considered to be in the inner arena when all four paws are in the area, and likewise, in : the perimeter, when all four paws are in the outer circle. Time spent in the inner area is expressed as a percent of total time in the inner and outer areas, and analyzed by = : one-way ANOVA followed by post-hoc Duncan’s tests for individual differences.
Results: (Figure 3) Compound 1 at 3.75 mg/kg ip. significantly increased the percent of time spent in the inner area of the arena as compared to control animals, reflecting an anxiolytic effect of treatment. bh) Isolation-induced vocalisation mode] of anxiety in the guinea pig pup
Animal models of psychiatric diseases commonly use rats or mice as experimental animals. However, guinea pigs here are more relevant experimental animals, since they possess central SHT;p receptors, similar to humans. Guinea pig vocalisations evoked by transient maternal separation is a test model for affective behaviour. Also, it is known that compounds capable of inhibiting isolation calls in this guinea pig model of anxiety are predictive of clinical effect.
Methods: Distress vocalisations of guinea-pig pups (2-14 days old) were quantified in a 5-min isolation period, after which they were reunited with their mothers and littermates. The test cage consisted of a sound-attenuating box with a white interior and white illumination. The vocalisations were recorded on DAT-tape by means of a microphone and a DAT recorder. Pups were first selected using the criterion of emitting a minimum of 500 vocalisations after three pre-tests on three consecutive days. Diazepam and the serotonin uptake inhibitor fluoxetine were included as : positive controls. Each pup received the test compound (Compound 1, 1-30 mg/kg, 1.p. in cyclodextrine 50%, diazepam 0.1-1 mg/kg, s.c. in CMC, or fluoxetine 1-10 mg/kg, s.c. in water vehicle), and was returned to the home cage for 30 min before maternal separation. Diazepam (1 mg/kg) was tested in parallel every day as a positive control. The difference in the number of calls emitted before and after treatment was counted and analysed by means of a paired ¢ test for each group. Percentage of reduction in the number of calls was analysed using a Kruskall-Wallis test followed : by a Mann-Whitney test between vehicle and different doses. - Results: Compound 1 significantly reduced the isolation-induced vocalisations, at all the doses studied. A single administration of Compound 1, 30 min before the test, dose-dependently (1-30 mg/kg, i.p.) increased the percentage of reduction in the number of calls, with an MED of 10 mg/kg. (Figure 4: Results are expressed as mean percentage of reduction + SEM. *P<0.05 vs vehicle group, Kruskall-Wallis test followed by Mann-Whitney test). This effect was superior to the one observed for diazepam (MED = 1 mg/kg; Figure 5). Higher doses of this compound were not included in the study because of sedation. Fluoxetine also reduced significantly the number of calls, with an MED of 10 mg/kg (Figure 5). It appears that both anxiolytic and antidepressant drugs reduce isolation calls emitted by guinea pigs. The bombesin antagonist Compound 1 was as effective as these compounds, indicating a potential for this class of compounds as novel anxiolytic/antidepressant agents. 2) PULMONARY HYPERTENSION
Hurel S.J. et al. (Lancet (1996) 348: 1243) have shown that infusion of a GRP receptor antagonist to a patient suffering from pulmonary hypertension was followed by a decrease in the pulmonary systolic pressure. The compounds of the instant invention are useful in the treatment of pulmonary hypertension as demonstrated by means of standard pharmacological procedures. 3) LUNG REPAIR AND LUNG DEVELOPMENT DISORDERS
Several studies have emphasized the role of GRP and the GRP receptor in lung repair after injury and in lung development (Spurzem J.R. et al. (1997) Am. J. Respir.
Cell. Mol. Biol . 16: 209-211; Wang D. . et al. (1996) Am. J. Respir. Cell. Mol. Biol.
14: 409-416; Spindel E.R., Ibidem 14: 407-408). Also, lung injury, including that induced by smoking, leads to increased levels of pulmonary bombesin-like peptides.
Findings by Cutz E. et al. (Pediatrics (1996) 98: 668-72) may suggest that maternal smoking potentiates hyperplasia of the pulmonary neuroendocrine cells (as measured by the percentage of airway epithelium immunoreactive for bombesin) in the lungs of — infants who die of sudden infant death syndrome (SIDS) and that a dysfunction of ) these cells may contribute to the pathophysiology of SIDS. The compounds of the instant invention are useful in the treatment of lung repair and lung development disorders as demonstrated by means of standard pharmacological procedures. 4) CANCER TREATMENT
The invention also relates to a method for treating cancer which comprises administering to a patient or a subject, particularly a mammal, more particularly a human, an effective amount of a compound of Formula I, optionally conjugated with a cytotoxic agent. The method is particularly useful in cancers where tumour cells have a cell surface bombesin receptor, including certain prostate or pancreatic cancers.
When a directly labelled compound of Formula I is used for therapeutic purposes, preferably a halogen substituent of Ar as a radionuclide is used. Preferably halogen radionuclides employed for therapy are PB-emitting or o-emitting radio- nuclides. The preferred halogen substituents of Ar for treating cancers include 1311, 211At, 76Br and 77Br, 1311 being particularly preferred.
Compounds of Formula I where Ar is substituted by a radionuclide halogen can easily be prepared via electrophilic aromatic substitution of a corresponding non- radioactive compound wherein Ar is substituted by a halide or an activating group. : Such a halide is preferably Br or I. Preferred activating groups include tributyl-tin, trimethylsilyl, t-butyldimethylsilyl, and the like.
Conjugation of a compound of Formula I with a cytotoxic agent is especially preferred when, in the compound of Formulal, R3 is hydroxy or amino. In such a case, the compounds of the invention may conveniently be linked to a cytotoxic agent, : using a bifunctional moiety like glutaric acid or the like to form a conjugate. Suitable cytotoxic agents include compounds such as doxorubicin, anticancer chemotherapy oo ~~ compounds such as those described in The Merck Index, 12th edition, 1996, p. MISC-
The use of a conjugate of a compound of Formula I with a radionuclide is also 10 provided by the instant invention; preferred radionuclides used for radiotherapy emit an a or § particle; they include 188Re, 1311 211 At 212py, 212g; 76Br, 77Br, and the like (for examples, The Merck Index, 12th edition, 1996, page MISC-93). Said conjugates may be prepared using conventional methods. For example, radionuclides such as 188Re can be linked to a compound of Formula I using a bifunctional chelating agent such as trisuccin (Safavy A. et al. (1993) Bioconj. Chem. 4: 194-8) according to a process adapted from Safavy A. et al. in Cancer (1997) 80 (Suppl): 2354-9. The conjugate may take the form of a compound which is cleaved to : release the cytotoxic agent on entry into the tumour cells. Compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, e.g. by hydrolysis upon entry into a target cell, are preferred.
A method of the present invention for treating a mammalian tumour includes administering to a mammal a composition including a tumour-inhibiting amount of at least one compound of the present invention. Such a tumour-inhibiting amount is an amount of at least one of the subject compounds which permits sufficient tumour localization of the compound to diminish tumour growth or size. This dosage can range from about 0.1 mmol/kg body weight to about 500 mmol/kg body weight. A - preferred dosage is about S to about 50 mmol/kg body weight.
The amount of radioactivity administered can vary depending on the type of radionuclide. However, with this in mind the amount of radioactivity which is administered can vary from about 1 millicurie (mCi) to about 800 mCi. Preferably, about 10 mCi to about 600 mCi is administered. Moreover when considering the dosage, the specific activity of the radioactive compound should be taken into : consideration. Such a specific activity is preferably very high, e.g. for 123I-labeled compounds the specific activity should be at least about 1,000 Ci/mM to about 50,000 — Ci/mM. More preferably the specific activity for 1231 1abeled compounds is, e.g., about 10,000 Ci/mM to about 22,000 Ci/mM. a) Prostate cancer
Bombesin specifically induces intracellular calcium mobilization via GRP receptors in human prostate cancer cells (Aprikian A.G. et al.(1996) J. Mol.
Endocrinol 16: 297-306). This may suggests that the bombesin family of neuropeptides could play a regulatory role in the biology of prostate cancer. The use of antibodies raised against bombesin inhibited the growth of a prostatic carcinoma . cell line (Hoosein N.M., (1993) Cancer Bull. 45:436-441). The compounds of the mvention are useful in the diagnosis and treatment of prostate cancer as demonstrated by means of standard pharmacological procedures. b) Pancreatic cancer
Normal and tumour pancreatic cells contain a specific GRP receptor that is expressed more on malignant pancreatic tissues (Hajri A. et al.(1996) Pancreas 12: 25-35). Bombesin-like peptides may stimulate proliferation of human pancreatic cancer cells (Wang Q.J. ef al. Int. J. Cancer (1996) 68: 528-34). As a consequence a } bombesin receptor antagonist may be used to treat pancreatic cancers. Furthermore, a radiolabelled bombesin receptor antagonist may be used to treat pancreatic cancers. : The compounds of the invention are useful in the treatment of pancreatic cancer as demonstrated by means of standard pharmacological procedures.
5) HEPATIC PORPHYRIA
The major clinical manifestation of hepatic porphyrias are neurologic : symptoms, including abdominal pain, neuropathy, and mental disturbances. It is believed that the neurologic symptoms are caused by an increase of a few - | gastrointestinal and neurotransmitter polypeptides, including GRP, in the systemic circulation during the acute phase of the disease (Medenica R. ef al. (1997) Cell mol.
Biol. 43: 9-27). Treatment with bombesin receptor antagonists may thus reduce the effects of those polypeptides that bind to bombesin receptors, and alleviate the symptomatology of acute porphyria. The compounds of the invention are useful in the treatment of hepatic porphyria as demonstrated by means of standard pharmacological procedures. 6) VISCERAL PAIN
The compounds used in the present invention are useful in visceral pain, as demonstrated by the following pharmacological procedure:
Irritated colon in rats
Under anesthesia, rats are tracheotomized and a carotid artery is cannulated for monitoring of blood pressure. Forty-five minutes after intracolonic injection of 0.6 % acetic acid, 3 colonic distensions (75 mmHg; 30 s) are performed. The colonic pain is evaluated by measurement of the fall of blood pressure after these colonic distensions.
Then the test compounds are administered subcutaneously, and 30 min later, 6 colonic distensions are performed again. The percentage of antinociception is computed by comparison of the blood pressure decrease in the pretreatment period with that of the post-treatment period. Using this procedure, Compound 1 at 10 mg/kg produced an ‘ antinociception of 57 %. 7) GASTROINTESTINAL SECRETORY DISTURBANCES
GRP has proved to be a particularly valuable tool in detecting disturbances of gastric secretory function, including those associated with duodenal ulcer disease and
Helicobacter pylori infection (McColl K.E. et al. (1995) Aliment. Pharmacol. Ther. 9: : 341-7). As a consequence, a radiolabelled bombesin receptor antagonist may be useful to diagnose these conditions. Other gastrointestinal functions such as — gallbladder “contraction, pancreatic secretion and gastro-esophageal motility are subject to regulatory controls by GRP, and a radiolabelled bombesin receptor antagonist may be useful to diagnose these conditions. The compounds of the invention are useful in the treatment of gastrointestinal secretory disturbances as demonstrated by means of standard pharmacological procedures. 8) EMESIS
Bombesin is present in high concentrations in the skin of frogs. As part of a defense reaction, Amphibia secrete emetic substances when swallowed by a predator.
In mammals, bombesin is widely distributed in the GI tract where it causes changes in gastric motility and secretion. Bombesin receptor antagonists of the invention may decrease retching and vomiting and thus be effective in the treatment of emesis, in particular in patients receiving anticancer agents. The following pharmacological procedure may be used to demonstrate the efficacy of the compounds of the invention in the treatment of emesis.
Antagonism of cisplatin-induced emesis in ferrets
The antiemetic properties of the compounds used in the present invention can be evidenced in vivo on cisplatin-induced emesis in ferrets, as compared to control animals, using the following procedure. Cisplatin (30 mg/kg) is injected by the iv. i route. Investigational compounds generally are injected by a parenteral route 30 min before administration of cisplatin, and again 45 min after the injection of the emetogen.
Following administration of the emetic substance, ferrets are observed continuously in individual cages during a 5-hour period. In each animal, the number of retching and vomiting episodes is counted for thie duration of the observation. Results represent the ) mean + S.E.M. for each treatment group. The significance of difference between treatment with an invention compound and with the vehicle (PEG 200; 0.5 ml/kg) is : assessed using a one-way analysis of variance (ANOVA) followed by a Student's t-test. — 9) ANOREXIA
Bombesin causes a decrease of glucose intake in mice. In mice lacking the
GRP receptor, bombesin no longer showed this effect (Hampton L. et al, Proc.
Natl. Acad. Sci. USA, 95: 3188-92, 1998). Bombesin receptor antagonists used in the present invention may increase feeding behavior, and thus be effective in the treatment of anorexia, such as the anorexia of cancer patients. Orexigenic effects of the compounds used in the instant invention can be evidenced in vivo by measuring the food intake and the bodyweight gain of mice, as compared to control animals. 10) PAIN
The compounds of the invention are useful in the treatment of pain as demonstrated by means of the following pharmacological models: a) Carrageenan-induced hyperalgesia and allodynia in the rat
Carrageenan (100 ul of 20 mg/ml) is administered into plantar surface of a hind paw. Hyperalgesia and allodynia to peripheral thermal and mechanical stimulation is measured. b) Ovario-hysterectomy model of surgical pain
Female rats are anesthetized with isoflurane (5% for induction, 2% for maintenance of anesthesia) and 1:4 O2/NO, mixture, which is maintained during surgery via a nose cone. Animals are then placed on a homeothermic blanket for the duration of the procedure. Ovario-hysterectomy is performed via a midline abdominal incision (2 cm in length) in the finea alba. The ovarian ligaments and the cervix are ligated with 5.0 silk, using single clamp technique. Four simple interrupted sutures : (5.0 silk) are placed in the abdominal wall. The skin is closed with four wound clips and the wound is treated with topical antibiotics.
The animals are tested post-operatively for signs of visceral nociception.
Immediately after surgery, animals are placed in an individual plexiglass cage and abdominal postures are recorded in 30 min batches. Postures scored are humpbacked position, contraction of the muscles of the abdomen associated with inward "movements of the hind limb, stretching of the body, and squashing of the lower abdomen against the floor. Animals are also tested for signs of referred hyperalgesia and allodynia in the hind paws. ¢) Diabetes-induced model of neuropathic pain
Diabetes is induced in rats (250 - 300 g) by a single i.p. injection of streptozocin (50 mg/kg) as described previously (Courteix et al., 1993, Pain 53: 81- 88). Control animals receive a similar administration of isotonic saline. d) Chronic constriction injury model of neuropathic pain
The chronic constriction injury (CCI) is induced as described previously by
Bennett and Xie, in Pain 33: 87-107 (1988). Briefly, rats (175-200g) are anesthetized with sodium pentobarbital 60 mg/kg i.p. The common left sciatic nerve is exposed at the level of the middle of the thigh by blunt dissection through biceps femoris, and proximal to the sciatic trifurcation, 4 ligatures (4.0 braided silk) are tied loosely : around it with about 1 mm spacing. The muscle is then closed in layers. Measurement of pain thresholds may be carried out according to several procedures, including: 1) Thermal hyperalgesia
Thermal hyperalgesia is assessed, before and at various time points afier drug administration, using the Ugo Basile Plantar test in rats, following a modified method : of Hargreaves et al. (1988) Pain 32: 77-88. Animals are habituated to the apparatus consisting of three individual perspex boxes on an elevated glass table. A mobile — tadiant heat source is located under the table and focused onto the desired paw. Paw oo withdrawal latencies are recorded. There is an automatic cut off point of 22.5 s to . prevent tissue damage. 2) Static allodynia
Mechanical hypersensitivity can be measured using Semmes-Weinstein von
Frey hairs. Animals are placed into wire mesh bottom cages allowing access to the underside of their paws; they are habituated to this environment prior to the start of the experiment. Mechanical hypersensitivity is tested by touching the plantar surface - of the animals’ right hind paw with von Frey hairs in ascending order of force (0.7, 1.2,1.5,2,3.6,5.5,8.5,11.8, 15.1 and 29 g) for up to 6 s. Once a withdrawal response is established, the paw is re-tested, starting with the next descending von Frey hair, until no response occurs. The highest force of 29 g lifts the paw as well as eliciting a response, thus represents the cut off point. The lowest amount of force (in g) required to elicit a response is recorded as the paw withdrawal threshold (PWT). 11) DIAGNOSTIC
The present invention provides a method for in vivo diagnostic imaging of a mammalian tissue which has cell surface bombesin receptors which includes administering to a mammal a diagnostic imaging amount of a compound of the . present invention and detecting an image of a tissue having an abundance of cells with bombesin receptors. In particular, the present invention provides methods for detecting certain types of cancer, e.g. prostate and pancreatic cancers.
The compounds used in the present invention bind to a cell surface bombesin receptor and exhibit intense cell specificity and affinity for the above cancerous cells and for cells having bombesin receptors. In one embodiment, the present invention is directed to a method for detecting a mammalian tumour which includes administering to a mammal a diagnostic imaging amount of a compound of Formula I above, and — ; "observing retention of the compound in a tissue of the mammal. The present invention further provides a method for diagnosing cancers using a labelled, preferably a bombesin receptor antagonist of Formula I labelled with an appropriate radionuclide suitable for imaging. Examples of radionuclides suitable for imaging are described by Michelot JM. ef al. (1991) in J. Nucl. Med. 32: 1573-80. Preferred radionuclides for diagnostic imaging do not emit a particle, e.g. an a or § particle.
When used for diagnostic imaging a halogen substituent of Ar as a radionuclide may be used. Moreover said halogen radionuclide groups which are preferably used for diagnostic imaging are mainly y-emitting radionuclides, which can be detected by radioimaging procedures, e.g. by scintigraphic imaging. Such y-emitting radionuclides emit radiation which is sufficently penetrating to be detected through tissues.
Preferred halogen substituents of Ar groups for diagnostic imaging include 1237 1241, 1251, 1317 18F, 76Br and 77Br. More preferred groups for diagnostic imaging include 1231, 1257 and 18F. 1231 js especially preferred for diagnostic imaging.
The present compounds can bind to a specific cell receptor prevalent on certain types of cancer cells. Such cancer cells include pancreatic carcinoma, prostate adenoma and related cells. An example of the cell receptor to which the present compounds bind is a cell surface bombesin receptor. The binding characteristics of the compounds used in the present invention have been evaluated in receptor binding . assays, as described in WO 98/07718. ; According to the present invention, a method for in vivo detecting a mammalian tumour or a tissue containing cell surface bombesin receptor includes administering to a mammal a composition including a diagnostic imaging amount of at least one of the present compounds. Such a diagnostic imaging amount is a dosage of at least one of the subject compounds which permits sufficient tumour or tissue localisation of the compound to allow detection of the tumour or tissue. This dosage can range from about 1 pg to about 1 g of the compound per litre which can be : administered in doses of about 1 ng/kg body weight to about 10 pg/kg body weight.
Preferred dosages of the present compounds are in the range of about 10 ng to about 2 — png’kg for diagnostic imaging. Moreover, for diagnostic imaging the amount of radioactivity administered should be considered. Preferably about 0.1 mCi to about 20 mCi of radioactive compound is administered.
As described herein a tumour or tissue labelled with one or more of the present compounds can be detected using a radiation detector, e.g. a y-radiation detector. One such procedure utilises scintigraphy. Tomographic imaging procedures such as single photon emission computed tomography (SPECT) or positron emission tomography (PET) can also be used to improve visualisation.
In another embodiment, the present invention provides a method for in vitro detection of a cancer cell in a mammalian tissue sample, which includes contacting a mammalian tissue sample with an in vitro diagnostic imaging amount of a compound of any one of Formulae I or II for a time and under conditions sufficient for binding of the compound to a cell surface bombesin receptor on the cancer cell, and detecting such binding. Samples can be collected by procedures known to the skilled artisan, e.g. by collecting a tissue biopsy or a body fluid. Samples can be sectioned, e.g. with a microtome, to facilitate microscopic examination and observation of bound compound. Samples can also be fixed with an appropriate fixative either before or after incubation with one of the present compounds to improve the histological quality } of sample tissues. Conditions sufficient for binding of the compound to a cell surface bombesin receptor on the cancer cell include standard tissue culture conditions, i.e. samples can be cultured in vitro and incubated with one of the present compounds in physiological media. Such conditions are well known to the skilled artisan.
Altematively, samples can be fixed and then incubated with a compound of the present invention in an isotonic or physiological buffer. An amount of at least one of the present compounds for in vitro detection of a cancer cell can range from about 1 ng/1 to about 1000 pg/l.
A preferred amount is about 1 pg/l to about 100 pg/l. : When the present compounds are used for in vitro diagnosis of cancer, a substituent of Ar as a radionuclide may be used.
Preferable substituent radionuclides === for in vitro diagnosis of cancer include 1251, 18g, .14COOH, -14CH3, 3H and the oo like.
For detection of cellular binding of one of the present compounds, samples can be incubated in the presence of a selected compound, then washed and counted in a standard scintillation counter.
Alternatively samples can be dipped in photographic emulsion and the signal detected under light microscopy after several days, as exposed silver grains.
Claims (21)
- CLAIMS . 1. Use, for the manufacture of a medicament for the treatment, prevention or diagnosis of any of anxiety and panic disorder, social phobia, pulmonary i hypertension, lung repair and lung development disorder; prostate cancer; pancreatic -- - cancer, hepatic porphyria, visceral pain, gastrointestinal secretory disturbance, inflammatory pain, neuropathic pain, cancer pain, postoperative pain, trigeminal neuralgia pain, acute herpetic pain and post herpetic pain, of a compound of Formula I rx EE EYE II A SSL RAN RE H, SG § R Re 0 Ar! @ or a pharmaceutically acceptable salt thereof wherein jisOorl; kisQorl; lis 0, 1, 2, or 3; misOorl; nis 0, 1 or2; Ar is phenyl, pyridyl or pyrimidyl, each unsubstituted or substituted by from 1 to 3 substituents selected from alkyl, halogen, alkoxy, acetyl, nitro, amino, - CHpNRIOR!I cyano, -CF3, -NHCONH),, and -COpR12; Rlis hydrogen or straight, branched, or cyclic alkyl of from 1 to 7 carbon atoms; R38 is hydrogen or forms a ring with RI of from 3 to 7 carbon atoms; R2 js hydrogen or straight, branched, or cyclic alkyl of from 1 to 8 carbon atoms which can also contain 1 to 2 oxygen or nitrogen atoms; R? is hydrogen or forms a ring of from 3 to 7 carbon atoms with RZ which can contain an oxygen or nitrogen atom; or R2 and RY can together be a carbonyl;Arl can be independently selected from Ar and can also include pyridyl-N- oxide, indolyl, imidazolyl, and pyridyl; R4, RS, RO, and R7 are each independently selected from hydrogen and : lower alkyl; R4 can also form with RS a covalent link of 2 to 3 atoms which may 5S include an oxygen or a nitrogen atom; LL i ~ R3can be independently selected from Ar or is hydrogen, hydroxy, -NMe», N-methyl-pyrrolyl, imidazolyl, N-methyl-imidazolyl, tetrazolyl, N-methyl- tetrazolyl, thiazolyl, -CONRI3R!4, alkoxy, 0 oO A= oo CF, Az © , Or Ar? CF, wherein pis 0, 1 or 2 and Ar? is phenyl or pyridyl; R10, R11 R12 RI3 and R14 are each independently selected from hydrogen or straight, branched, or cyclic alkyl of from 1 to 7 carbon atoms.
- 2. Use according to claim 1, wherein the compound is of Formula II RS R7 6 Pie 0, TN L R, I[0] Ar! a ) wherein Ar is phenyl unsubstituted or substituted with 1 or 2 substituents selected from isopropyl, halo, nitro, and cyano; R4, R5, and RO are hydrogen; R7 is methyl or hydrogen; R3 is 2-pyridyl or hydroxy; andAr! is indolyl, pyridyl, pyridyl-N-oxide, or imidazolyl.
- 3. Use, for the manufacture of a medicament for the treatment, prevention or . diagnosis of any of anxiety and panic disorder, social phobia, pulmonary hypertension, lung repair and lung development disorder, prostate cancer, pancreatic cancer, hepatic. porphyria, visceral pain, gastrointestinal secretory disturbance, inflammatory pain, neuropathic pain, cancer pain, postoperative pain, trigeminal neuralgia pain, acute herpetic pain and post herpetic pain, of (S) 3-(1H-indol-3-yl)-N- [1-(5-methoxy-pynidin-2-yl)-cyclohexylmethyl]-2-methyl-2-[3-(4-nitro-phenyl)- ureido]-propionamide or a pharmaceutically acceptable salt thereof.
- 4. Use according to any of claims 1-3, wherein the medicament is for the treatment or prevention of a gastrointestinal secretary disturbance which is duodenal ulcer or Helicobacter pylori infection.
- 5. Use of a compound of the formula I defined in claim 1 or of the formula II defined in claim 2 or of the compound of claim 3 in the manufacture of a medicament for the diagnostic imaging in a mammal of a mammalian tumour.
- 6. Use according to claim 5, wherein the group Ar in said compound is phenyl substituted with a y-emitting radionuclide halogen.
- 7. Use according to claim 5, wherein the group Ar in said compound is phenyl substituted with 123, 124, 1257, 1317, 18F, 76Br, or 77Br.
- 8. Use of a compound of the formula I defined in claim 1 or of the formula II defined in claim 2 or of the compound of claim 3 in the manufacture of a medicament for the treatment of prostate cancer or pancreatic cancer.
- 9. Use of a conjugate of a cytotoxic agent with a compound of the formula I defined in claim 1 or of the formula II defined in claim 2 or of the compound of claim 3 in the manufacture of a medicament for the treatment of a mammalian tumour.
- 10. The use of claim 9, wherein the conjugate becomes cleaved to release the oo cytotoxic agent on entry into tumour cells. oo
- 11. The use of claim 8, 9 or 10, wherein the group Ar in said compound is phenyl substituted with a B-emitting or an a-emitting radionuclide halogen.
- 12. The use of claim 8, 9 or 10, wherein the group Ar in said compound is phenyl substituted with 1311, 211 A¢ 76Br, or 77Br.
- 13. Use according to claim 9, wherein the conjugate comprises a radionuclide linked to a compound of formula I by a chelating agent.
- 14. Use according to claim 13, wherein the radionuclide is '**Re.
- 15. The use of any of claims 5 to 14, wherein the medicament is directed to a mammalian tumour which comprises cancer cells which have cell surface bombesin receptors.
- 16. A method for in vitro detection of a cancer cell in a mammalian tissue sample which includes contacting said mammalian tissue sample with an in vitro diagnostic amount of a compound of the formula I defined in claim 1 or of the formula IT defined in claim 2 or of the compound of claim 3. }
- 17. The method of claim 16, wherein the group Ar in said compound is phenyl substituted with a f-emitting or an a-emitting radionuclide halogen.
- 18. The method of claim 16, wherein the group Ar in said compound is phenyl substituted with 1313 21 1At, 76Br, or ’7gr.
- 19. The method of claim 16, 17 or 18, wherein the test is for a tissue sample that contains cancer cells having cell surface bombesin receptors.
- 20. Use according to any one of claims 1, 3,5, 8 or 9, substantially as herein described and exemplified and/or described with reference to the accompanying figures.
- 21. The method of claim 16, Substantially ag herein described and exemplified and/or described with reference to the accompanying figures. p+ 7DED SHEET
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200303723A ZA200303723B (en) | 2003-05-14 | 2003-05-14 | Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200303723A ZA200303723B (en) | 2003-05-14 | 2003-05-14 | Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders. |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200303723B true ZA200303723B (en) | 2004-06-30 |
Family
ID=33453097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200303723A ZA200303723B (en) | 2003-05-14 | 2003-05-14 | Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200303723B (en) |
-
2003
- 2003-05-14 ZA ZA200303723A patent/ZA200303723B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2731471T3 (en) | Compositions, methods and systems for the synthesis and use of imaging agents | |
CN111225911B (en) | Compounds and compositions for treating hematological disorders | |
KR101483831B1 (en) | Compositions and methods for treating colitis | |
US20090041663A1 (en) | Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors | |
TW201034690A (en) | Technetium-and rhenium-bis (heteroaryl) complexes and methods of use thereof for inhibiting PSMA | |
CN101589026A (en) | Method of treatment of glioma brain tumour | |
JP2016530285A (en) | Halogenated compounds for imaging and treatment of cancer and methods of use thereof | |
UA120353C2 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
JP6570042B2 (en) | Functionalized benzopyran compounds and uses thereof | |
CN104053439A (en) | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid | |
ES2267153T3 (en) | NK-1 RECEPTOR ANTAGONISTS OF THE CNS AS ANTIDEPRESSIVE AGENTS AND / OR ANTIANSIEDAD. | |
CA2839350A1 (en) | The use of serotonin receptor agonists for treatment of movement disorders | |
BR112019016827A2 (en) | 5-membered azaheterocyclic delta-opioid receptor modulating compounds, methods of use and production thereof | |
BR112019010127A2 (en) | psychotropic agents and their uses | |
CA3121483A1 (en) | An aurora a kinase inhibitor for use in the treatment of neuroblastoma | |
AU2014318748B2 (en) | Novel anthranilic amides and the use thereof | |
EP1343498A1 (en) | Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders | |
BR112012020060B1 (en) | USE OF N-((1-((4-HYDROXITETRAHYDRO-2H-PIRAN-4-YL)METHYL)PIPERIDIN-4-YL)METHYL)-3-ISOPROPYL-2-OXO-2,3-DIHYDRO-1H-BENZO [D]ImidAZOLE-1-CARBOXAMIDE TO TREAT ALZHEIMER'S DISEASE AND DEMENTIA | |
EP0652879B1 (en) | 1-azaadamantane derivatives as 5-ht4 agonists or antagonists and/or 5-ht3 antagonists | |
TWI296522B (en) | Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients | |
BR112020020961A2 (en) | CANCER TREATMENT METHODS | |
ZA200303723B (en) | Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders. | |
ES2689665T3 (en) | Compounds and methods to treat leukemia | |
CN107108560A (en) | Compound, composition and its method | |
ES2935705T3 (en) | A ligand of the GABA A receptor |